Streetbeat News

Earnings

NKE

Nike Inc (NYSE:NKE) shares fell after reporting Q3 results that beat estimates but provided guidance suggesting a challenging path ahead. Analysts adjusted their price targets and ratings, acknowledging Nike's strategic shifts towards innovation, sports focus, inventory reduction, and wholesale presence improvement. These changes are expected to impact sales and profitability negatively in the short term, particularly in the first half of 2025. However, analysts see these steps as necessary for long-term growth and margin expansion, with some viewing the stock's current weakness as a buying opportunity.

Portfolio Pulse from Chris Katje

March 22, 2024 | 2:44 pm

MTNB

Matinas BioPharma Holdings Inc (NYSE:MTNB) reported a complete clinical response in three patients with invasive fusarium infection treated with MAT2203, leading to a 13.70% increase in its stock price. The patients were part of the Compassionate/Expanded Use Access Program, showcasing MAT2203's effectiveness where other treatments failed or were not viable due to side effects. This success bolsters confidence for the upcoming ORALTO Phase 3 trial in invasive aspergillosis patients.

Portfolio Pulse from Vandana Singh

March 22, 2024 | 2:37 pm

AIR

AAR Corp's shares declined following the announcement of mixed financial results for the third quarter. The company's performance did not fully meet market expectations, leading to a negative reaction in its stock price.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 2:35 pm

FDX

MRNO

SMLP

WS

Worthington Steel, Inc. (WS) reported strong Q3 results, surpassing earnings and sales expectations, leading to an 18.8% stock price increase. Other stocks like Murano Global Investments PLC (MRNO), Summit Midstream Partners, LP (SMLP), and FedEx Corporation (FDX) also saw significant gains due to various positive developments.

Portfolio Pulse from Avi Kapoor

March 22, 2024 | 2:08 pm

CSIQ

JKS

JinkoSolar's Q4 profits were supported by government subsidies amid falling prices and overcapacity in the solar sector. The company forecasts accelerated consolidation, with the top 10 producers controlling 90% of the market by year-end. JinkoSolar's stock dropped 10.5% post-announcement, underperforming peers like Canadian Solar. Despite challenges, JinkoSolar plans to increase production capacity and remains financially stable with significant cash reserves.

Portfolio Pulse from The Bamboo Works

March 22, 2024 | 2:04 pm

REKR

Rekor Systems (NASDAQ:REKR) is scheduled to release its quarterly earnings report on March 25, 2024, with an expected EPS of $-0.10. Historical performance shows a pattern of share price drops following earnings misses. Shares are currently trading at $1.95, up 36.62% over the last year. Investors are advised to watch for the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 2:02 pm

TMC

TMC Metals (NASDAQ:TMC) is scheduled to release its quarterly earnings report on March 25, 2024, with analysts expecting an EPS of $-0.16. The company's past earnings performance shows a mix of beats and misses, with the stock price reacting variably. Shares have risen 103.09% over the last year, trading at $1.76 as of March 21. Investors are advised to pay attention to the company's guidance for future growth, which can significantly impact the stock price.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 2:01 pm

VNRX

VolitionRX (AMEX:VNRX) is scheduled to release its quarterly earnings report on Monday, 2024-03-25, with analysts expecting an EPS of $-0.11. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat leading to a 1.29% drop. Shares are currently trading at $0.73, down 56.57% over the last year, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 2:01 pm

TOVX

Theriva Biologics (AMEX:TOVX) is scheduled to release its quarterly earnings report on March 25, 2024, with analysts expecting an EPS of $-0.41. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat resulting in a 10.86% drop. Shares have decreased by 19.06% over the last year, indicating potential concern among long-term shareholders ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 2:01 pm

LUCD

Lucid Diagnostics (NASDAQ:LUCD) is scheduled to release its quarterly earnings report on March 25, 2024, with an expected EPS of $-0.26. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows that Lucid Diagnostics has previously beaten EPS estimates, leading to significant share price movements. Currently, the stock is trading at $1.11, reflecting a 26.43% decrease over the last year.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 2:01 pm